The Johns Hopkins University;Northwestern University
发明人:
申请号：
EP19169083.3
公开号：
EP3536345A1
申请日:
2015.05.06
申请国别(地区):
EP
年份:
2019
代理人:
摘要：
Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific Ti-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific T1 contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA-targeted imaging in vivo.86Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.
